EP 1787649 A1 20070523 - Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
Title (en)
Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
Title (de)
Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
Title (fr)
Utilisation d'une combinaison de valérate d'oestradiol et dienogest en tant que contraceptif oral, pour le traitement de l'hémorragie utérine dysfonctionnelle
Publication
Application
Priority
EP 05022324 A 20051013
Abstract (en)
Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate, a second phase consisting of 2 groups of daily dose units of the combination, where the first group contains 5 daily dose units and the second group contains 17 daily dose, and a third phase consisting of 2 daily dose units. Use of estradiol valerate with 17alpha -cyanomethyl-17-beta -hydroxyestra-4,9-diene-3-one (dienogest) for producing a multi-phase combination preparation for the oral therapy of the dysfunctional uterine bleeding, in the form of oral contraceptives. The combination of estradiol valerate with dienogest comprises a first phase consisting of 2 daily dose units of estradiol valerate at 3 mg, a second phase consisting of 2 groups of daily dose units, where the first group contains 5 daily dose units of a combination of 2 mg estradiol valerate and 2 mg of dienogest and the second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate and 3 mg of dienogest, a third phase consisting of 2 daily dose units having 1 mg of estradiol valerate and an additional phase consisting of 2 daily dose units on a pharmaceutically harmless placebo. The entire daily dose units of the multi-phase combination corresponds to 28 days. ACTIVITY : Contraceptive; Gynecological. MECHANISM OF ACTION : None given.
IPC 8 full level
A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61P 15/00 (2006.01); A61P 15/18 (2006.01)
CPC (source: EP KR)
A61K 31/565 (2013.01 - EP KR); A61K 31/57 (2013.01 - EP KR); A61P 5/30 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 15/18 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
C-Set (source: EP)
Citation (search report)
- [XY] EP 0770388 A1 19970502 - JENAPHARM GMBH [DE]
- [Y] EP 0696454 A2 19960214 - JENAPHARM GMBH [DE]
- [ET] WO 2005102247 A2 20051103 - SCHERING AG [DE], et al
- [XY] GRASER T ET AL: "Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest: A dose-ranging study", MATURITAS, vol. 35, no. 3, 30 June 2000 (2000-06-30), pages 253 - 261, XP002369505, ISSN: 0378-5122
- [X] VON SCHOULTZ B: "Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment.", CLIMACTERIC : THE JOURNAL OF THE INTERNATIONAL MENOPAUSE SOCIETY. AUG 2003, vol. 6 Suppl 2, August 2003 (2003-08-01), pages 24 - 32, XP009062446, ISSN: 1369-7137
- [AD] DAVIS A ET AL: "Triphasic Norgestimate-Ethinyl Estradiol for Treating Dysfunctional Uterine Bleeding", OBSTETRICS AND GYNECOLOGY, NEW YORK, NY, US, vol. 96, no. 6, December 2000 (2000-12-01), pages 913 - 920, XP002317447, ISSN: 0029-7844
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK YU
DOCDB simple family (publication)
WO 2007042296 A1 20070419; AR 056694 A1 20071017; AT E424828 T1 20090315; AT E497387 T1 20110215; CA 2623024 A1 20070419; CA 2623024 C 20120306; CL 2011000283 A1 20110708; CN 101312733 A 20081126; CY 1110321 T1 20150114; CY 1111406 T1 20150805; DE 502005006837 D1 20090423; DE 502006008853 D1 20110317; DK 1787649 T3 20090602; DK 1933843 T3 20110418; DO P2006000221 A 20070831; EP 1787649 A1 20070523; EP 1787649 B1 20090311; EP 1933843 A1 20080625; EP 1933843 B1 20110202; ES 2322479 T3 20090622; ES 2360302 T3 20110602; HR P20090256 T1 20090630; JP 2009511526 A 20090319; JP 2013047269 A 20130307; JP 5735200 B2 20150617; KR 101218872 B1 20130107; KR 20080065651 A 20080714; KR 20100082389 A 20100716; ME 01056 B 20121020; PE 20070555 A1 20070712; PE 20100090 A1 20100312; PL 1787649 T3 20090831; PL 1933843 T3 20110630; PT 1787649 E 20090508; PT 1933843 E 20110429; SI 1787649 T1 20090831; SI 1933843 T1 20110630; TW 200731977 A 20070901; TW 200829255 A 20080716; TW I328453 B 20100811; UY 29861 A1 20070531
DOCDB simple family (application)
EP 2006009867 W 20061012; AR P060104489 A 20061013; AT 05022324 T 20051013; AT 06806225 T 20061012; CA 2623024 A 20061012; CL 2011000283 A 20110210; CN 200680038181 A 20061012; CY 091100621 T 20090611; CY 111100422 T 20110502; DE 502005006837 T 20051013; DE 502006008853 T 20061012; DK 05022324 T 20051013; DK 06806225 T 20061012; DO 2006000221 A 20061013; EP 05022324 A 20051013; EP 06806225 A 20061012; ES 05022324 T 20051013; ES 06806225 T 20061012; HR P20090256 T 20090505; JP 2008534936 A 20061012; JP 2012253067 A 20121119; KR 20087011203 A 20080509; KR 20107014574 A 20061012; ME P17109 A 20051013; PE 2006001241 A 20061012; PE 2009001256 A 20061012; PL 05022324 T 20051013; PL 06806225 T 20061012; PT 05022324 T 20051013; PT 06806225 T 20061012; SI 200530672 T 20051013; SI 200630991 T 20061012; TW 95137564 A 20061012; TW 96100872 A 20070109; UY 29861 A 20061013